Emergence of resistance to chloramphenicol among vancomycin-resistant enterococcal (VRE) bloodstream isolates

被引:16
作者
Lautenbach, E
Gould, CV
LaRosa, LA
Marr, AM
Nachamkin, I
Bilker, WB
Fishman, NO
机构
[1] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Med,Div Infect Dis, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Pharm, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[5] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[6] Univ Penn, Sch Med, CERTs, Philadelphia, PA 19104 USA
关键词
chloramphenicol; antimicrobial resistance; VRE;
D O I
10.1016/j.ijantimicag.2003.09.011
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Therapeutic options for vancomycin-resistant enterococcal (VRE) bloodstream infections are extremely limited. Chloramphenicol is effective when VRE isolates are susceptible to this agent. However, longitudinal trends in chloramphenicol-resistant VRE (CR-VRE) are unknown. The possible association between CR-VRE and antibiotic use has not been studied. We analyzed the antimicrobial susceptibility profiles of all VRE blood isolates from 1991-2000 at our institution. We performed a correlational study to examine the relationship between annual hospital-wide use of specific antibiotics and antibiotic classes and CR-VRE prevalence. During the 10-year study period, the prevalence of CR-VRE increased from 0 to 11% (P < 0.001, trend). CR-VRE prevalence was correlated only with chloramphenicol use (P = 0.05) and quinolone use (P = 0.01). If these trends continue, dependence on newer, more expensive agents will increase. The correlation between both chloramphenicol use and quinolone use and the prevalence of CR-VRE suggests that efforts to preserve the utility of chloramphenicol in VRE infections may depend on optimizing the use of these agents. (C) 2003 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:200 / 203
页数:4
相关论文
共 20 条
[1]   Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon [J].
Alekshun, MN ;
Levy, SB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2067-2075
[2]   Quinupristin/dalfopristin: A therapeutic review [J].
Allington, DR ;
Rivey, MP .
CLINICAL THERAPEUTICS, 2001, 23 (01) :24-+
[3]   TESTS FOR LINEAR TRENDS IN PROPORTIONS AND FREQUENCIES [J].
ARMITAGE, P .
BIOMETRICS, 1955, 11 (03) :375-386
[4]   Thrombocytopenia associated with linezolid therapy [J].
Attassi, K ;
Hershberger, E ;
Alam, R ;
Zervos, MJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :695-698
[5]   Nosocomial bloodstream infections in United States hospitals: A three-year analysis [J].
Edmond, MB ;
Wallace, SE ;
McClish, DK ;
Pfaller, MA ;
Jones, RN ;
Wenzel, RP .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (02) :239-244
[6]  
FACKLAM RR, 1995, MANUAL CLIN MICROBIO, V6, P308
[7]   Linezolid: An oxazolidinone antimicrobial agent [J].
Fung, HB ;
Kirschenbaum, HL ;
Ojofeitimi, BO .
CLINICAL THERAPEUTICS, 2001, 23 (03) :356-391
[8]   Nosocomial spread of linezolid-resistant, vancomycin-resistant enterococcus faecium [J].
Herrero, IA ;
Issa, NC ;
Patel, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (11) :867-869
[9]   Enterococcal bacteremia: Risk factors for vancomycin resistance and predictors of mortality [J].
Lautenbach, E ;
Bilker, WB ;
Brennan, PJ .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1999, 20 (05) :318-323
[10]   The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus [J].
Lautenbach, E ;
Schuster, MG ;
Bilker, WB ;
Brennan, PJ .
CLINICAL INFECTIOUS DISEASES, 1998, 27 (05) :1259-1265